Moors & Cabot, Inc. Regeneron Pharmaceuticals, Inc. Transaction History

Moors & Cabot, Inc.

$2.02 Billion
Q4 2024

A detailed history of Moors & Cabot, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Moors & Cabot, Inc. holds 785 shares of REGN stock, worth $554,947. This represents 0.03% of its overall portfolio holdings.

Number of Shares

785

Previous 797 1.51%

Holding current value

$554,947

Previous $837,000 33.21%

% of portfolio

0.03%

Previous 0.04%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 07, 2025	SELL	$701.85 - $1046.91 $8,422 - $12,562	-12 Reduced 1.51%	785 $559,000
Q3 2024 Nov 08, 2024	SELL	$1024.09 - $1201.76 $19,457 - $22,833	-19 Reduced 2.33%	797 $837,000
Q2 2024 Aug 09, 2024	SELL	$883.2 - $1071.19 $44,160 - $53,559	-50 Reduced 5.77%	816 $857,000
Q1 2024 May 08, 2024	BUY	$902.69 - $993.35 $22,567 - $24,833	25 Added 2.97%	866 $833,000
Q4 2023 Feb 14, 2024	BUY	$775.18 - $881.7 $1,550 - $1,763	2 Added 0.24%	841 $738,000
Q3 2023 Nov 07, 2023	BUY	$692.45 - $844.37 $29,775 - $36,307	43 Added 5.4%	839 $690,000
Q2 2023 Aug 09, 2023	BUY	$700.03 - $830.35 $1,400 - $1,660	2 Added 0.25%	796 $571,000
Q1 2023 May 04, 2023	BUY	$680.49 - $826.97 $4,763 - $5,788	7 Added 0.89%	794 $652,000
Q4 2022 Feb 09, 2023	SELL	$705.89 - $766.39 $137,648 - $149,446	-195 Reduced 19.86%	787 $567,000
Q4 2022 Feb 06, 2023	BUY	$705.89 - $766.39 $131,295 - $142,548	186 Added 23.37%	982 $708,000
Q3 2022 Nov 07, 2022	SELL	$573.97 - $724.32 $37,308 - $47,080	-65 Reduced 7.55%	796 $548,000
Q2 2022 Aug 08, 2022	SELL	$548.35 - $738.84 $156,828 - $211,308	-286 Reduced 24.93%	861 $509,000
Q1 2022 May 13, 2022	SELL	$595.12 - $698.43 $23,804 - $27,937	-40 Reduced 3.37%	1,147 $801,000
Q4 2021 Feb 14, 2022	SELL	$543.48 - $670.97 $91,304 - $112,722	-168 Reduced 12.4%	1,187 $750,000
Q3 2021 Dec 08, 2021	SELL	$574.03 - $680.96 $30.8 Million - $36.5 Million	-53,645 Reduced 97.54%	1,355 $818,000
Q3 2021 Nov 05, 2021	BUY	$574.03 - $680.96 $30.8 Million - $36.6 Million	53,738 Added 4258.16%	55,000 $61,000
Q2 2021 Aug 10, 2021	BUY	$472.8 - $558.54 $6,146 - $7,261	13 Added 1.04%	1,262 $705,000
Q1 2021 May 12, 2021	BUY	$446.73 - $548.2 $196,561 - $241,208	440 Added 54.39%	1,249 $585,000
Q4 2020 Feb 11, 2021	BUY	$478.3 - $607.98 $13,870 - $17,631	29 Added 3.72%	809 $384,000
Q3 2020 Nov 09, 2020	BUY	$544.75 - $658.21 $46,848 - $56,606	86 Added 12.39%	780 $437,000
Q2 2020 Aug 13, 2020	BUY	$493.32 - $643.92 $73,998 - $96,588	150 Added 27.57%	694 $433,000
Q1 2020 May 12, 2020	SELL	$336.18 - $494.43 $19,498 - $28,676	-58 Reduced 9.63%	544 $264,000
Q1 2019 May 01, 2019	BUY	$372.08 - $439.57 $223,992 - $264,621	602 New	602 $246,000
Q1 2018 May 18, 2018	SELL	$315.82 - $393.78 $189,492 - $236,267	-600 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$358.63 - $469.95 $41,242 - $54,044	115 Added 23.71%	600 $227,000
Q3 2017 Nov 16, 2017	BUY	$431.38 - $504.0 $209,219 - $244,440	485	485 $217,000

Others Institutions Holding REGN

# of Institutions

1,489

Shares Held

85.7M

Call Options Held

1.53M

Put Options Held

1.44M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.8B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Moors & Cabot, Inc. with notifications on news.

Account